CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.
CinCor Pharma was formed in August 2005 and is located in the San Francisco Bay area. The company was founded by Dr. Stephen G. Keneally and Thomas Miller, who had met while at Millennium Pharmaceuticals in 2000.
CinCor Pharma's mission is to discover, develop and commercialize life-saving treatments to address unmet medical needs and improve patients’ lives.
CinCor Pharma’s vision is to be the leader in the discovery and development of innovative drug treatments and technologies to significantly improve the lives of patients.
Mr. Michael W. Kalb CPA (Exec. VP, CFO & Principal Accounting Officer)
Ms. Ida Hatoum (Sr. VP and Head of People, Talent & Culture)
Hema Keshava (Corp. Controller)
Recognition and Awards
CinCor Pharma has received numerous awards for its commitment to innovation, creativity and leadership in the life sciences industry.